ClinicalTrials.gg
CompletedNCT02460289Updated Aug 1, 2023Results posted

Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia

An interventional study of Treatment: Minoxidil 5% / Botanical Hair Solution for Men in Male Pattern of Hair Loss, Androgenic Alopecia, sponsored by Galderma R&D. Completed at 1 site in United States. Open to male participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Galderma R&D (part of Galderma Group AG) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing minoxidil in Alopecia — 10 open to participants now, 12 under way, 3 of them phase 3. Minoxidil · Alopecia.

Enrollment
14th of 31
63 · median 60
Started
2015
with 2 others
No phase
8 of 31
3 open now
Registered
7th of 31
by date
Lead sponsor
2 of 31
Galderma R&D

Among the 31 studies testing minoxidil in Alopecia, this one is the 14th largest by enrollment, is one of 3 that started in 2015, is one of 8 with no phase, and was the 7th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

10 of the 31 studies testing minoxidil in Alopecia are open now, in 5 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About minoxidil

Minoxidil: first FDA approval 1979 (LONITEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 74 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 46 (62%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 60 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing minoxidil in Alopecia, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the effect of Minoxidil 5% Foam and Botanical Hair Solution Regimen in men with thinning hair and male pattern hair loss/androgenic alopecia (Norwood III \& IV).

03

Conditions studied

  • Male Pattern of Hair Loss, Androgenic Alopecia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male patients age 18 to 60 years at the time of enrollment.
  2. Men who have self-perceived thinning hair.
  3. Men who have presentation of male pattern hair loss/androgenic alopecia (Norwood III \& IV).

Key Exclusion Criteria:

  1. History of allergic reactions or severe intolerance to minoxidil and Botanical Hair Solution product ingredients.
  2. Plan to use any other concomitant therapy to treat hair loss, regrowth or volume during the study.

3 Subjects taking or planning to take topical or systemic prescription or OTC medications for treating hair loss and/or hair volume.

  1. Any significant history of concurrent medical disease, which in the judgment of the Investigator, would make the subject inappropriate for entry to this study including history of skin disease that may confound study results.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Treatment

    Drug: Treatment: Minoxidil 5% / Botanical Hair Solution for Men

Interventions

  • DrugTreatment: Minoxidil 5% / Botanical Hair Solution for Men

    Drug page: Minoxidil

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Investigator's Rating of Standardized Global Photographs at Week 12

    The Investigator or a trained grader rated each participant's standardized global photographs for improvement from baseline for parameters like hair thinning, hair growth, impression of scalp hair coverage and overall perception of treatment benefit using a 1-to-7-point Likert scale. Investigator global photograph rating were assessed using 7-point Likert scale. Each score on the individual scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree.

    Time frame: At Week 12

  2. Change From Baseline in Participant Rating at Week 12

    Participants rated the parameters like appearance of hair, growth of hair, satisfaction with hairline at the front of the head, satisfaction with hair on the top of the head and satisfaction with hair overall as an overall improvement from the baseline by conducting their own assessments by looking in a mirror and evaluating improvement from baseline using a 1 to 7-point Likert scale. Each score on the individual scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree.

    Time frame: At Week 12

Secondary outcomes

  1. Mean Change From Baseline in Shed Hair Count

    Participants collected their hair full day, including after combing and hair-washing. Participants turned in these hair collections at each visit. The results were averaged weekly. Mean change from baseline in hair wash/shed hair count was reported at Week 12.

    Time frame: At Week 12

  2. Number of Participant in Each Response Category Based on Subject Satisfaction Questionnaire

    Participant's satisfaction questionnaire was used to specifically collect the participants' feedback on the treatment regimen, the level of satisfaction and future usage. Participants were asked to complete a cosmetic acceptability questionnaire. This 10 item questionnaire had a 5-point Likert Response Scale (1=Strongly Agree; 5=Strongly Disagree).

    Time frame: At Week 4,6 and 12

Other outcomes

  1. Number of Participants With Adverse Events (AEs)

    AEs were defined as any untoward medical occurrence associated with the use of a study product in humans, whether or not considered study product related. An AE could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study product and would not imply any judgment about causality. An AE could arise with any use of the study product and with any route of administration, formulation, or dose, including an overdose. Thus, any new sign, symptom or disease, or clinically significant increase in the intensity of an existing sign, or symptom would be considered as an AE. Any new clinically relevant sign or symptom suffered by the participant, which appeared after the study procedures was reported as an AE. Any worsening in scalp dryness or itch score from baseline was also reported as an AE. The Investigator or designee had the final authorization to determine if a reaction was considered an AE.

    Time frame: From start of study up to Week 12

07

Results

Posted Aug 1, 2023

Participant flow

The study was conducted in the United States from 19 May 2015 to 19 September 2015.

Participant flow — Overall Study
MilestoneMinoxidil 5% Foam and Botanical Hair Solution for Men
Started63
Intent to treat (itt) population56
Safety population (sp)61
Completed53
Not completed10
Withdrew: Adverse event1
Withdrew: Withdrawal by subject8
Withdrew: Lost to follow-up1

Outcome measures

PrimaryChange From Baseline in Investigator's Rating of Standardized Global Photographs at Week 12

The Investigator or a trained grader rated each participant's standardized global photographs for improvement from baseline for parameters like hair thinning, hair growth, impression of scalp hair coverage and overall perception of treatment benefit using a 1-to-7-point Likert scale. Investigator global photograph rating were assessed using 7-point Likert scale. Each score on the individual scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree.

Time frame:
At Week 12
Reported as:
Mean · Score on a scale
Change From Baseline in Investigator's Rating of Standardized Global Photographs at Week 12
Score on a scaleMinoxidil 5% Foam and Botanical Hair Solution for Men
Hair Thinning5.0 ± 0.9
Hair Growth5.1 ± 0.9
Impression of scalp hair coverage5.1 ± 0.9
Overall perception of treatment benefit5.1 ± 0.9
PrimaryChange From Baseline in Participant Rating at Week 12

Participants rated the parameters like appearance of hair, growth of hair, satisfaction with hairline at the front of the head, satisfaction with hair on the top of the head and satisfaction with hair overall as an overall improvement from the baseline by conducting their own assessments by looking in a mirror and evaluating improvement from baseline using a 1 to 7-point Likert scale. Each score on the individual scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree.

Time frame:
At Week 12
Reported as:
Mean · Score on a scale
Change From Baseline in Participant Rating at Week 12
Score on a scaleMinoxidil 5% Foam and Botanical Hair Solution for Men
Appearance of hair5.4 ± 1.2
Growth of hair5.3 ± 1.3
Satisfaction with hairline at the front of the head4.9 ± 1.4
Satisfaction with hair on the top of the head5.0 ± 1.5
Satisfaction with hair overall as an overall improvement5.2 ± 1.4
SecondaryMean Change From Baseline in Shed Hair Count

Participants collected their hair full day, including after combing and hair-washing. Participants turned in these hair collections at each visit. The results were averaged weekly. Mean change from baseline in hair wash/shed hair count was reported at Week 12.

Time frame:
At Week 12
Reported as:
Mean · Shed Hair Count
Mean Change From Baseline in Shed Hair Count
Shed Hair CountMinoxidil 5% Foam and Botanical Hair Solution for Men
Mean Change From Baseline in Shed Hair Count14.1 ± 21.6
SecondaryNumber of Participant in Each Response Category Based on Subject Satisfaction Questionnaire

Participant's satisfaction questionnaire was used to specifically collect the participants' feedback on the treatment regimen, the level of satisfaction and future usage. Participants were asked to complete a cosmetic acceptability questionnaire. This 10 item questionnaire had a 5-point Likert Response Scale (1=Strongly Agree; 5=Strongly Disagree).

Time frame:
At Week 4,6 and 12
Reported as:
Count of participants · Participants
Number of Participant in Each Response Category Based on Subject Satisfaction Questionnaire
ParticipantsMinoxidil 5% Foam and Botanical Hair Solution for Men
Satisfaction with appearance of hair (At Week 4) — Agree27
Satisfaction with appearance of hair (At Week 4) — Disagree8
Satisfaction with appearance of hair (At Week 4) — Neutral21
Satisfaction with appearance of hair (At Week 6) — Agree42
Satisfaction with appearance of hair (At Week 6) — Disagree4
Satisfaction with appearance of hair (At Week 6) — Neutral10
Satisfaction with appearance of hair (At Week 12) — Agree44
Satisfaction with appearance of hair (At Week 12) — Disagree4
Satisfaction with appearance of hair (At Week 12) — Neutral8
Satisfaction with growth of hair (At Week 4) — Agree26
Satisfaction with growth of hair (At Week 4) — Disagree12
Satisfaction with growth of hair (At Week 4) — Neutral18
Satisfaction with growth of hair (At Week 6) — Agree40
Satisfaction with growth of hair (At Week 6) — Disagree5
Satisfaction with growth of hair (At Week 6) — Neutral11
Satisfaction with growth of hair (At Week 12) — Agree44
Satisfaction with growth of hair (At Week 12) — Disagree7
Satisfaction with growth of hair (At Week 12) — Neutral5
Satisfaction with hairline at the front of the head (At Week 4) — Agree21
Satisfaction with hairline at the front of the head (At Week 4) — Disagree16
Satisfaction with hairline at the front of the head (At Week 4) — Neutral19
Satisfaction with hairline at the front of the head (At Week 6) — Agree26
Satisfaction with hairline at the front of the head (At Week 6) — Disagree10
Satisfaction with hairline at the front of the head (At Week 6) — Neutral20
Satisfaction with hairline at the front of the head (At Week 12) — Agree34
Satisfaction with hairline at the front of the head (At Week 12) — Disagree8
Satisfaction with hairline at the front of the head (At Week 12) — Neutral14
Satisfaction with hair on the top of the head (At Week 4) — Agree21
Satisfaction with hair on the top of the head (At Week 4) — Disagree16
Satisfaction with hair on the top of the head (At Week 4) — Neutral19
Satisfaction with hair on the top of the head (At Week 6) — Agree36
Satisfaction with hair on the top of the head (At Week 6) — Disagree7
Satisfaction with hair on the top of the head (At Week 6) — Neutral13
Satisfaction with hair on the top of the head (At Week 12) — Agree37
Satisfaction with hair on the top of the head (At Week 12) — Disagree7
Satisfaction with hair on the top of the head (At Week 12) — Neutral12
Satisfaction with hair overall as an overall improvement from the baseline (At Week 4) — Agree21
Satisfaction with hair overall as an overall improvement from the baseline (At Week 4) — Disagree13
Satisfaction with hair overall as an overall improvement from the baseline (At Week 4) — Neutral22
Satisfaction with hair overall as an overall improvement from the baseline (At Week 6) — Agree34
Satisfaction with hair overall as an overall improvement from the baseline (At Week 6) — Disagree5
Satisfaction with hair overall as an overall improvement from the baseline (At Week 6) — Neutral17
Satisfaction with hair overall as an overall improvement from the baseline (At Week 12) — Agree39
Satisfaction with hair overall as an overall improvement from the baseline (At Week 12) — Disagree6
Satisfaction with hair overall as an overall improvement from the baseline (At Week 12) — Neutral11
Other pre-specifiedNumber of Participants With Adverse Events (AEs)

AEs were defined as any untoward medical occurrence associated with the use of a study product in humans, whether or not considered study product related. An AE could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study product and would not imply any judgment about causality. An AE could arise with any use of the study product and with any route of administration, formulation, or dose, including an overdose. Thus, any new sign, symptom or disease, or clinically significant increase in the intensity of an existing sign, or symptom would be considered as an AE. Any new clinically relevant sign or symptom suffered by the participant, which appeared after the study procedures was reported as an AE. Any worsening in scalp dryness or itch score from baseline was also reported as an AE. The Investigator or designee had the final authorization to determine if a reaction was considered an AE.

Time frame:
From start of study up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsMinoxidil 5% Foam and Botanical Hair Solution for Men
Number of Participants With Adverse Events (AEs)4

Adverse events

Collected over From Start of Study up to Week 12. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Minoxidil 5% Foam and Botanical Hair Solution for Men0/61 (0%)0/61 (0%)4/61 (6.6%)
Most frequent other events
Most frequent other events
EventMinoxidil 5% Foam and Botanical Hair Solution for Men
Pain (crown of head)General disorders1/61
BronchitisRespiratory, thoracic and mediastinal disorders1/61
Joint InjuryMusculoskeletal and connective tissue disorders1/61
Middle ear effusionEar and labyrinth disorders1/61

Baseline characteristics

SP included all participants who were enrolled and received at least one dose of study product.

Age, Continuous
Age, Continuous(years)Minoxidil 5% Foam and Botanical Hair Solution for Men
Mean45.1 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Minoxidil 5% Foam and Botanical Hair Solution for Men
Female0
Male61
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Minoxidil 5% Foam and Botanical Hair Solution for Men
American Indian or Alaska Native3
Asian4
Black or African American6
Hispanic or Latino11
White37
Fitzpatrick Skin Type
Fitzpatrick Skin Type(Participants)Minoxidil 5% Foam and Botanical Hair Solution for Men
II6
III32
IV18
V5
08

Study locations

1 site
  • Stephens & Associates
    Richardson, Texas 75081, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Nov 2015, 6 months.

Results were first posted in Aug 2023, 7 years 9 months after primary completion.

Of 61 industry-sponsored interventional studies with no phase under Alopecia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 6 months is below that.

Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2015
First posted
Jun 2, 2015
StartActual
May 19, 2015
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Results first posted
Aug 1, 2023
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02460289
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jun 2, 2015
Start date
May 19, 2015
Primary completion
Nov 2015
Completion
Nov 2015
Results posted
Aug 1, 2023
Last update
Aug 1, 2023

Study contacts

Warren Winkelman, MD, PhD, MBA
study director · Galderma R&D

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Minoxidil

Start the discussion